288330 — Bridge Biotherapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩58bn
- KR₩44bn
- KR₩100m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 72,241 | 57,943 | 43,128 | 51,295 | 20,183 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,717 | 1,797 | 415 | 987 | 856 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 78,710 | 60,304 | 44,426 | 54,957 | 21,731 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 645 | 830 | 664 | 3,784 | 4,287 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 79,737 | 63,510 | 46,657 | 61,455 | 32,683 |
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,708 | 1,055 | 3,556 | 7,494 | 10,375 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Liabilities | 4,719 | 4,282 | 3,610 | 9,590 | 13,382 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 75,018 | 59,228 | 43,047 | 51,865 | 19,301 |
Total Liabilities & Shareholders' Equity | 79,737 | 63,510 | 46,657 | 61,455 | 32,683 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |